Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small molecule PD-L1 inhibitor, in chronic hepatitis B (CHB) subjects

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small molecule PD-L1 inhibitor, in chronic hepatitis B (CHB) subjects

	AASLD 2025 Nov 7-11 Wash DC Edward Gane1